Hexapeptide ghrelin-receptor agonist
GHRP-2
Hexapeptide ghrelin receptor agonist for GH release research.
- Half-life~30 minutes plasma
- Dose range100 to 300 mcg per administration, 1 to 3 times daily · 8 to 12 week cycle
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
GHSR-1a receptor agonist. Stimulates GH release with mild cortisol elevation. Less selective than Ipamorelin.
Research
What the research shows.
Stronger GH-release magnitude than GHRP-6. Slightly less clean profile than Ipamorelin. Research base focuses on GH-axis research and recovery applications.
GHRP-2 is a synthetic hexapeptide that activates the GH-secretagogue receptor. More potent than GHRP-6 in raw GH release but with a slightly less clean profile (mild cortisol elevation in some research).
Research-context use overlaps with Ipamorelin in the GH-pulse stack category. Researchers typically pick one, not both, with Ipamorelin preferred for the cleanest profile.
Contraindications
When not to use.
Active malignancy. Cushing-spectrum disorders. Pregnancy. Pediatric use without clinical oversight.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.